Drug profile · INN
dolutegravir, emtricitabine and tenofovir alafenamide
DOLUTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
dolutegravir, emtricitabine and tenofovir alafenamide (DOLUTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
Frequently asked questions
What is dolutegravir, emtricitabine and tenofovir alafenamide?
dolutegravir, emtricitabine and tenofovir alafenamide (DOLUTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for dolutegravir, emtricitabine and tenofovir alafenamide?
DOLUTEGRAVIR, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE is a marketed brand name for dolutegravir, emtricitabine and tenofovir alafenamide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dolutegravir, emtricitabine and tenofovir alafenamide?
dolutegravir, emtricitabine and tenofovir alafenamide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.